Pinschewer Daniel D
Division of Experimental Virology, Department of Biomedicine, University of Basel, Switzerland.
Swiss Med Wkly. 2017 Aug 8;147:w14465. doi: 10.4414/smw.2017.14465. eCollection 2017.
Vaccines represent one of the most successful chapters in the history of medicine. Over the past decades, the advent of recombinant cDNA technology has enabled the biomedical community to genetically engineer viruses for vaccine delivery purposes. As a starting point, this review evaluates the unmet medical needs, which drive scientists and industry to exploit such fundamentally new technology for human vaccination. The author discusses the molecular functioning, production and safety profile of replication-competent and -deficient viral vector systems, representing two fundamentally distinct classes of "genetic vaccines". Building upon this knowledge, he dissects the immunological mechanisms rendering immune responses to viral vectors qualitatively and quantitatively distinct from those elicited by non-live vaccination approaches. These mechanisms comprise (1) the vectors' innate immune recognition by the host cell, (2) potent priming of CD8+ cytotoxic T cells as a result of dendritic cell targeting and endogenous protein synthesis, (3) conformational antigen display for protective antibody induction as well as (4) prolonged availability of substantial quantities of antigen. Deduced from these features, preferential indications for virally vectored vaccines are discussed, taking into consideration specific medical needs as well as risk-benefit assessments of replicating vector systems. The limitations and challenges in virally vectored vaccination must also be given careful consideration. Pre-existing and vaccination-induced anti-vector immunity can interfere with vaccine immunogenicity and prime-boost vaccination, respectively. Additionally, the requirement for eukaryotic production systems imposes technological as well as regulatory hurdles. Existing strategies to overcome these challenges are outlined. With the recent licensure of the first virally vectored vaccine this review seems timely to herald the introduction of virally vectored vaccines into daily medical practice.
疫苗是医学史上最成功的篇章之一。在过去几十年里,重组cDNA技术的出现使生物医学界能够对病毒进行基因工程改造,以用于疫苗递送。作为开篇,本综述评估了尚未满足的医疗需求,这些需求促使科学家和业界利用这种全新的技术进行人类疫苗接种。作者讨论了具有复制能力和缺陷的病毒载体系统的分子功能、生产和安全性概况,这两类系统代表了两种根本不同的“基因疫苗”。基于这些知识,他剖析了使针对病毒载体的免疫反应在质量和数量上与非活疫苗接种方法引发的免疫反应不同的免疫机制。这些机制包括:(1)宿主细胞对载体的天然免疫识别;(2)由于树突状细胞靶向和内源性蛋白质合成而对CD8 + 细胞毒性T细胞的有效启动;(3)用于诱导保护性抗体的构象抗原展示;以及(4)大量抗原的长期可用性。从这些特征出发,结合特定的医疗需求以及对复制载体系统的风险效益评估,讨论了病毒载体疫苗的优先适用症。病毒载体疫苗接种的局限性和挑战也必须得到认真考虑。预先存在的和疫苗诱导的抗载体免疫分别会干扰疫苗的免疫原性和初免 - 加强疫苗接种。此外,对真核生产系统的要求带来了技术和监管方面的障碍。概述了克服这些挑战的现有策略。随着首款病毒载体疫苗的近期获批,本综述似乎适时地预示着病毒载体疫苗将引入日常医疗实践。